CL2016003290A1 - Tratamiento de hipertrigliceridemia severa. - Google Patents

Tratamiento de hipertrigliceridemia severa.

Info

Publication number
CL2016003290A1
CL2016003290A1 CL2016003290A CL2016003290A CL2016003290A1 CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1 CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A CL2016003290 A CL 2016003290A CL 2016003290 A1 CL2016003290 A1 CL 2016003290A1
Authority
CL
Chile
Prior art keywords
treatment
severe hypertriglyceridemia
severe
hypertriglyceridemia
hypertrigliceridemia
Prior art date
Application number
CL2016003290A
Other languages
English (en)
Inventor
Pol Boudes
Yun-Jung Choi
Robert L Martin
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of CL2016003290A1 publication Critical patent/CL2016003290A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>USO DEL ACIDO <em>(R)</em>-2-(4-((2-ETOXI-3-(4-(TRIFLUOROMETIL)FENOXI)PROPIL)TIO)-2-METILFENOXI)ACETICO O UNA SAL DEL MISMO PARA TRATAR HIPERTRIGLICERIDEMIA SEVERA.</p>
CL2016003290A 2014-06-26 2016-12-22 Tratamiento de hipertrigliceridemia severa. CL2016003290A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26

Publications (1)

Publication Number Publication Date
CL2016003290A1 true CL2016003290A1 (es) 2017-09-08

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003290A CL2016003290A1 (es) 2014-06-26 2016-12-22 Tratamiento de hipertrigliceridemia severa.

Country Status (16)

Country Link
US (1) US20150374649A1 (es)
EP (1) EP3160458A1 (es)
JP (1) JP2017519028A (es)
KR (1) KR20170020514A (es)
CN (1) CN106470675A (es)
AU (1) AU2015279905A1 (es)
BR (1) BR112016028918A2 (es)
CA (1) CA2951280A1 (es)
CL (1) CL2016003290A1 (es)
EA (1) EA201790091A1 (es)
HK (1) HK1231380A1 (es)
IL (1) IL249757A0 (es)
MX (1) MX2016017081A (es)
PH (1) PH12016502415A1 (es)
SG (1) SG11201610243YA (es)
WO (1) WO2015200580A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SI3119384T1 (sl) 2014-03-20 2018-12-31 Cymabay Therapeutics, Inc. Zdravljenje intrahepatičnih holestatičnih bolezni
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301050B2 (en) 2003-09-19 2007-11-27 Janssen Pharmaceutical N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
JP2013523746A (ja) * 2010-03-30 2013-06-17 ノバルティス アーゲー Ｄｇａｔ１阻害剤の使用

Also Published As

Publication number Publication date
MX2016017081A (es) 2017-05-01
CN106470675A (zh) 2017-03-01
AU2015279905A1 (en) 2017-02-02
WO2015200580A1 (en) 2015-12-30
EA201790091A1 (ru) 2017-07-31
KR20170020514A (ko) 2017-02-22
BR112016028918A2 (pt) 2017-08-22
HK1231380A1 (zh) 2017-12-22
IL249757A0 (en) 2017-02-28
US20150374649A1 (en) 2015-12-31
PH12016502415A1 (en) 2017-02-27
JP2017519028A (ja) 2017-07-13
EP3160458A1 (en) 2017-05-03
SG11201610243YA (en) 2017-01-27
CA2951280A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
CL2016003290A1 (es) Tratamiento de hipertrigliceridemia severa.
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2016001215A1 (es) Tratamiento de hipercolesterolemia familiar homocigota.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CL2016002971A1 (es) Combinación.
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
MD3233803T2 (ro) Procedeu pentru prepararea unui compus diariltiohidantoină
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201691582A1 (ru) Новые фармацевтические препараты
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
MA53399A (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
EP3137903A4 (en) Flexible optical biosensor for point of use multi-pathogen detection
AR103680A1 (es) Inhibidores selectivos de bace1
CY1122264T1 (el) Ppar ενωσεις για χρηση στην αντιμετωπιση των ινωτικων νοσων
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
NI201800071A (es) Compuestos de isoindol
GB201413826D0 (en) Plasma treatment of an infected nail or infected skin
MD3233823T2 (ro) Procedee pentru prepararea unui compus diariltiohidantoină
EA201791174A1 (ru) Антимикотическое соединение
EP3092013A4 (en) Sterilization of topical antiseptic solutions
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы